ChromaDex® (OTCBB: CDXC) Announces Financial Results for the Year Ended 2011

Boston, MA 3/16/12 (StreetBeat) -- ChromaDexCorporation (OTCBB: CDXC) an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries, today announced financial results for the fiscal year ended December 31, 2011. ChromaDex announced total revenues, prepared in accordance with United States Generally Accepted Accounting Principles (GAAP) of approximately $8.1 million and a net loss attributable to common stockholders of $0.12 per share for the fiscal year ended December 31, 2011. As of December 31, 2011, cash, cash equivalents and marketable securities totaled over $420,000. Subsequent to the fiscal year ended December 31, 2011, ChromaDex raised capital of approximately $10.1 million in net proceeds through the sale of its common stock.

"Going into 2012, we are now poised to leverage our product and service offerings related to BluScience™, pTeroPure® and other novel ingredients. Our goal is to build ChromaDex into a leader in the natural products industry," said Jeffrey Himmel, CEO of ChromaDex.

"2011 was truly a landmark year for ChromaDex as the company launched its new dietary supplement product line, BluScience, into the market. Initial distribution of our BluScience products was achieved at a major drug chain and health food store as well as an online retailer. This was the first step in the BluScience national mass-market roll out plan," said Debra Heim, COO and President of the Consumer Products Division of ChromaDex.

Additional Financial Results & Notes

ChromaDex recorded revenue of $8,112,610 during the year of 2011 as compared to $7,566,370 in 2010, representing year on year growth of 7 percent. The net loss attributable to common stockholders for the fiscal year ended December 31, 2011, was $7,894,984 as compared to a net loss of $2,051,676 in 2010. The net loss in the year of 2011 was largely impacted by an increase in non-cash, share-based compensation expense related to the stock options that were granted following the May 20, 2010 private placement and other non-cash compensation. The effect of this increase, which is a "non-GAAP measure," decreased the net loss for the year of 2011 by $2,969,150 and decreased the loss per share for the year of 2011 by $0.04.

About ChromaDex®:

ChromaDex, Inc., a wholly owned and operated subsidiary of ChromaDex, is an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries. ChromaDex, Inc. has an expanding pipeline of new ingredients, including its pTeroPure® (http://www.pteropure.com) pterostilbene for which it has worldwide, exclusive patent pending rights. ChromaDex recently launched its BluScience™ (http://www.bluscience.com) line of dietary supplements. Capitalizing on the diverse potential applications of the product, ChromaDex is also developing pTeroPure for the pharmaceutical markets, among others. pTeroPure is currently being studied in a human clinical trial at the University of Mississippi.

StreetBeat Disclaimer

Distributed by Viestly

ChromaDex (CDXC) Stock Chart Analysis Video

The ChromaDex chart is rising in 2012. The MACD/PPS are showing a positive divergence while the RSI is gaining momentum. Watch for bottom support at 50 cents to hold and for increases in volume to potentially push the stock towards initial resistance at 65 cents.

Distributed by Viestly

ChromaDex Announces Completion of Patient Enrollment for the First Human Clinical Study of its Proprietary pTeroPure

Palm Beach, FL 12/19/11 (StreetBeat) -- ChromaDex Corporation (OTCBB: CDXC), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food and beverage, cosmetic and pharmaceutical industries today announced the successful completion of enrollment in the first human clinical study of its proprietary pTeroPure.

The purpose of the randomized, double-blind placebo-controlled study is to evaluate whether pTeroPure will lower cholesterol and blood pressure, as well as improve markers for oxidative stress in patients with dyslipidemia-meeting inclusion criteria. Investigators are also evaluating the safety of pTeroPure in these patients.

pTeroPure is ChromaDex's proprietary brand of its patent-pending pterostilbene, a central ingredient in its recently launched BluScience™ line of dietary supplements, now available at GNC.

Pterostilbene is one of several stilbenes found in blueberries and other berries that have demonstrated pre-clinical benefits in a number of health factors including improved levels of cholesterol, blood pressure and oxidative stress.

ChromaDex holds exclusive worldwide rights to patents pending for pterostilbene for these and other health benefits based on technology licensed from the University of Mississippi , as well as through additional intellectual property developed by the company or in conjunction with leading research institutions.

William Spengler , President of ChromaDex, said, "Now that trial enrollment is successfully completed, we anticipate release of the trial data in Q2 2012. This first human clinical study of pTeroPure will provide an important independent clinical assessment of what we believe is an enormous opportunity with this product. We anticipate that additional clinical studies involving pTeroPure and other compounds in our pipeline will be initiated in the coming months."

pTeroPure was recently named the 2010 North American Most Promising Ingredient of the Year by the prestigious independent research company Frost & Sullivan. Capitalizing on the diverse potential applications of the product, ChromaDex is also developing pTeroPure for the skincare and pharmaceutical markets, among others.

StreetBeat Disclaimer

Distributed by Viestly